Nov 2026· Frontiers in Aging Neuroscience· Vol 18, pp.
1987345
· 0 citations· 262 references
Medicine
TL;DR
This structured narrative review presents a multilevel conceptual framework for comparing how protein pathology relates to synaptic and network dysfunction, cellular maintenance, glial responses and systemic conditions, an evidence map rather than a quantitative network or validated treatment algorithm.
Abstract
Amyloid-β (Aβ) plaques and Alzheimer-type tau pathology are the neuropathological hallmarks of Alzheimer's disease, but their burden does not fully explain variation in vulnerability, symptoms or progression. This structured narrative review presents a multilevel conceptual framework for comparing how protein pathology relates to synaptic and network dysfunction, cellular maintenance, glial responses and systemic conditions. Its contribution is a set of relationship-specific appraisal rules: a driver, mediator, amplifier or modifier role must be supported for a defined outcome, biological setting and stage, with human associations distinguished from experimental causal tests. Roles remain unassigned when evidence cannot discriminate among causal contributions, responses and compensation. Threshold, topography and tempo organize heterogeneity without defining validated subtypes. Measurements must match the biological process and intended use; biomarker change cannot by itself establish clinical benefit. Therapeutic reasoning considers stage, co-pathology, safety, delivery conditions and patient priorities. Four provisional predictions concern post-onset complement inhibition in a tauopathy model, frailty-related modification of pathology-clinical coupling, the predictive value of complementary measurements and incremental clinical benefit from a conditional combination strategy. Each specifies the comparison and findings that would weaken the proposed relationship or use. The framework is an evidence map rather than a quantitative network or validated treatment algorithm. Its narrative evidence base and uneven human causal support limit generalization; prospective evaluation is required to establish added explanatory, predictive or clinical value.
Abstract Alzheimer’s disease (AD) usually follows a slowly progressive course, but some patients experience unusually rapid cognitive and functional decline. This clinical phenotype, commonly termed rapidly progressive Alzheimer’s disease (rpAD), has no consensus definition; its status as a distinct biological entity r...
Mei-Ling Cao, Lu-Ming Leng, Ping Liu et al.· Clinical Interventions in Ag...· 0 citations
A practical multi-axis framework comprising clinical phenotype, AD biological context (AD pathology plus co-pathologies and molecular modifiers), network topography (regional patterns) and tempo (rate of clinical and biomarker progression) is proposed to reduce diagnostic mismatches, make cohorts more comparable and su...
L. Grinberg, M. Murray· Nature Reviews Neurology· 0 citations
This review proposes conceptualizing Alzheimer's disease as a neural circuit disorder that emerges from sustained crosstalk among multiple interacting pathways, including brain injury, neuroinflammation, mitochondrial and metabolic dysfunction, neurovascular dysfunction, neurovascular dysfunction, synaptic dysfunction,...
Desh Deepak Singh· Current Neuropharmacology· 0 citations
This comprehensive review synthesizes current knowledge across the full spectrum of AD, encompassing molecular pathophysiology (amyloid cascade, tau hyperphosphorylation, and neuroinflammation), genetic architecture, genetic architecture (familial mutations and APOE-mediated risk), evolving biomarker-based diagnostic f...
Azzam Zrineh, Rami Akwan, Roaa Darawsheh et al.· 0 citations
Alzheimer's disease (AD) is characterized by marked heterogeneity in the timing and extent of neuronal dysfunction and degeneration. Specific neuronal populations, including entorhinal cortex layer II stellate cells, hippocampal CA1 pyramidal neurons, basal forebrain cholinergic neurons, locus coeruleus noradrenergic n...
Tian-Yang Xu, E. Er-deng, Ting Zhang et al.· Ageing Research Reviews· 0 citations
Alzheimer’s disease remains a major global health challenge, with limited disease-modifying therapies and a rapidly growing societal burden. Although amyloid and tau remain central to the field, current evidence also implicates neuroinflammation, immune dysregulation, vascular dysfunction, and host-microbe interactions...
J. A. Rice, Jean-Marie C. Bouteiller, A. Khachaturian· Frontiers in Molecular Medic...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.